SMSLIFE Stock Overview
SMS Lifesciences India Limited manufactures, buys, imports, and sells active pharmaceutical ingredients (API) and its intermediates, organic and inorganic chemicals, and pharmaceuticals in India.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹740.25|
|52 Week High||₹1,024.90|
|52 Week Low||₹469.75|
|1 Month Change||-2.28%|
|3 Month Change||-5.70%|
|1 Year Change||24.63%|
|3 Year Change||9.34%|
|5 Year Change||n/a|
|Change since IPO||448.94%|
Recent News & Updates
SMS Lifesciences India's (NSE:SMSLIFE) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for SMS Lifesciences India Limited's ( NSE:SMSLIFE ) stock hasn't...
|SMSLIFE||IN Pharmaceuticals||IN Market|
Return vs Industry: SMSLIFE exceeded the Indian Pharmaceuticals industry which returned 9.5% over the past year.
Return vs Market: SMSLIFE underperformed the Indian Market which returned 34.4% over the past year.
|SMSLIFE Average Weekly Movement||7.3%|
|Pharmaceuticals Industry Average Movement||5.9%|
|Market Average Movement||6.8%|
|10% most volatile stocks in IN Market||9.8%|
|10% least volatile stocks in IN Market||4.1%|
Stable Share Price: SMSLIFE is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SMSLIFE's weekly volatility (7%) has been stable over the past year.
About the Company
|1990||523||Talluri Veera Venkata Murthy||https://www.smslife.in|
SMS Lifesciences India Limited manufactures, buys, imports, and sells active pharmaceutical ingredients (API) and its intermediates, organic and inorganic chemicals, and pharmaceuticals in India. The company offers APIs in various therapeutic areas, such as antiulcer, antifungal, and erectile dysfunction. It also provides consultancy services.
SMS Lifesciences India Fundamentals Summary
|SMSLIFE fundamental statistics|
Is SMSLIFE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SMSLIFE income statement (TTM)|
|Cost of Revenue||₹2.25b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||71.57|
|Net Profit Margin||6.94%|
How did SMSLIFE perform over the long term?See historical performance and comparison
0.2%Current Dividend Yield
Is SMS Lifesciences India undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SMSLIFE (₹740.25) is trading below our estimate of fair value (₹785.15)
Significantly Below Fair Value: SMSLIFE is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SMSLIFE is good value based on its PE Ratio (10.3x) compared to the Indian Pharmaceuticals industry average (25.9x).
PE vs Market: SMSLIFE is good value based on its PE Ratio (10.3x) compared to the Indian market (23.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SMSLIFE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SMSLIFE is good value based on its PB Ratio (1.6x) compared to the IN Pharmaceuticals industry average (3.3x).
How is SMS Lifesciences India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SMS Lifesciences India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has SMS Lifesciences India performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SMSLIFE has a large one-off gain of ₹77.8M impacting its September 30 2021 financial results.
Growing Profit Margin: SMSLIFE's current net profit margins (6.9%) are higher than last year (3.6%).
Past Earnings Growth Analysis
Earnings Trend: SMSLIFE's earnings have grown by 8.2% per year over the past 5 years.
Accelerating Growth: SMSLIFE's earnings growth over the past year (185.4%) exceeds its 5-year average (8.2% per year).
Earnings vs Industry: SMSLIFE earnings growth over the past year (185.4%) exceeded the Pharmaceuticals industry 29.7%.
Return on Equity
High ROE: SMSLIFE's Return on Equity (15.2%) is considered low.
How is SMS Lifesciences India's financial position?
Financial Position Analysis
Short Term Liabilities: SMSLIFE's short term assets (₹1.4B) do not cover its short term liabilities (₹1.4B).
Long Term Liabilities: SMSLIFE's short term assets (₹1.4B) exceed its long term liabilities (₹566.7M).
Debt to Equity History and Analysis
Debt Level: SMSLIFE's net debt to equity ratio (42%) is considered high.
Reducing Debt: SMSLIFE's debt to equity ratio has increased from 31.8% to 45.2% over the past 5 years.
Debt Coverage: SMSLIFE's debt is well covered by operating cash flow (56.5%).
Interest Coverage: SMSLIFE's interest payments on its debt are well covered by EBIT (5.9x coverage).
What is SMS Lifesciences India current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SMSLIFE's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.3%).
High Dividend: SMSLIFE's dividend (0.2%) is low compared to the top 25% of dividend payers in the Indian market (1.33%).
Stability and Growth of Payments
Stable Dividend: SMSLIFE has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: SMSLIFE has only been paying a dividend for 2 years, and since then payments have not increased.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (2.1%), SMSLIFE's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Talluri Veera Venkata Murthy (61 yo)
Mr. Talluri Veera Venkata Satyanarayana Murthy had been a Non-Executive Director at SMS Pharmaceuticals Limited since 2019 until May 28, 2021. Mr. Murthy serves as Managing Director of SMS Lifesciences Ind...
CEO Compensation Analysis
Compensation vs Market: Talluri Veera Venkata's total compensation ($USD323.44K) is above average for companies of similar size in the Indian market ($USD37.95K).
Compensation vs Earnings: Talluri Veera Venkata's compensation has been consistent with company performance over the past year.
Experienced Management: SMSLIFE's management team is considered experienced (4.6 years average tenure).
Experienced Board: SMSLIFE's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SMSLIFE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SMS Lifesciences India Limited's employee growth, exchange listings and data sources
- Name: SMS Lifesciences India Limited
- Ticker: SMSLIFE
- Exchange: NSEI
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹2.238b
- Shares outstanding: 3.02m
- Website: https://www.smslife.in
Number of Employees
- SMS Lifesciences India Limited
- Plot No. 19-III
- Road No. 71
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 16:00|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.